 |
 |
 |
 |
|
|
|
|
 |
|
 |
|
 |
|
 |
|
 |
|
 |
|
 |
|
 |
|
 |
|
 |
|
 |
|
 |
|
 |
|
 |
|
 |
|
Your Online Resource for Diabetes Treatment
Home > Glossary > IGTIGT |
Abbreviation for impaired glucose tolerance. |
 |
|
 |
Articles |
 |
Events |
 |
Slides |
 |
Misc. Content |
| Keyword Match |
 |
1. Alogliptin Study 010: Exploratory Endpoints of Alogliptin Therapy vs Placebo |
| •DeFronzo et al conducted a 26-week, double-blind, placebo-controlled, phase-3 trial to evaluate the efficacy and safety of alogliptin, a dipeptidyl peptidase-4 inhibitor, in treatment-naïve patients with type ... | |
|
2. Prevalence of IFG, IGT, and Prediabetes According to a Combination of Central Obesity and Hyperinsulinemia |
| •Li and colleagues analyzed data from the National Health and Nutrition Examination Survey 2005–2006 to estimate the prevalence of impaired fasting glucose (IFG), impaired glucose tolerance (IGT), and prediabetes among US adolescents aged 12–19 years. • Fasting plasma glucose (FPG ... | |
|
3. Prevalence of IFG, IGT, and Prediabetes by Cardiometabolic Risk Factors |
| •Li and colleagues analyzed data from the National Health and Nutrition Examination Survey 2005–2006 to estimate the prevalence of impaired fasting glucose (IFG), impaired glucose tolerance (IGT), and prediabetes among US adolescents aged 12–19 years. •Fasting plasma glucose (FPG ... | |
 |
4. Prevalence of pre-diabetes and its association with clustering of cardiometabolic risk factors and hyperinsulinemia among U.S. adolescents: National Health and Nutrition Examination Survey 2005-2006 |
| OBJECTIVE: Impaired fasting glucose (IFG) and/or impaired glucose tolerance (IGT) are considered t ... | |
|
5. Differences in glucose tolerance between fixed-dose antihypertensive drug combinations in people with metabolic syndrome |
| Bakris G, Molitch M, Hewkin A, Kipnes M, Sarafidis P, Fakouhi K, Bacher P, Sowers J, for the STAR Investigators We sought to test the hypothesis that a fixed-dose combin ... | |
|
6. All pre-diabetes is not the same: metabolic and vascular risks of impaired fasting glucose at 100 versus 110 mg/dl: the Screening for Impaired Glucose Tolerance study 1 (SIGT 1) |
| Phillips LS, Weintraub WS, Ziemer DC, Kolm P, Foster JK, Vaccarino V, Rhee MK, Budhwani RK, Caudle JM (No Abstract Availab ... | |
|
7. Type 2 Diabetes in the United States: Overview |
| Data are derived from the 1999-2003 National Health Interview Survey (NHIS), 1999-2002 National Health and Nutrition Examination Survey (NHANES), 2003 Indian Health Service, and 2005 resident population estimates. The total number of patients wit ... | |
|
8. Impact of intensive lifestyle and metformin therapy on cardiovascular disease risk factors in the diabetes prevention program |
| Impact of intensive lifestyle and metformin therapy on cardiovascular disease risk factors in the Diabetes Prevention ProgramRatner R, Goldberg R, Haffner S, Marcovina S, Orchard T, Fowler S, Temprosa M OBJECTIVE: The Diabetes Prevention Program demonstrated the ability to delay or prevent type 2 d ... | |
|
9. Strategies to Identify Adults at High Risk for Type 2 Diabetes: The Diabetes Prevention Program |
| The Diabetes Prevention Program OBJECTIVE: The Diabetes Prevention Program (DPP) was a large, multicenter, randomized clinical trial testing interventions to prevent or delay type 2 diabetes. A major chal ... | |
|
10. Diabetes, Insulin Resistance, and the Metabolic Syndrome in Patients With Acute Myocardial Infarction Without Previously Known Diabetes |
| Diabetes Care Tenerz Å, MD1,2, Norhammar A, MD3, Silveira A, PhD4, Hamsten A, MD, PhD3,4, Nilsson G, MD, PhD1,2, Rydén L, MD, PhD3, Malmberg K, MD, PhD3 1 Departme ... | |
|
11. Low Insulin Sensitivity (Si = 0) in Diabetic and Nondiabetic Subjects in the Insulin Resistance Atherosclerosis Study. Is it associated with components of the metabolic syndrome and nontraditional risk factors? |
| Diabetes Care Haffner SM, MD1, D’Agostino R, Jr., PhD2, Festa A, MD1, Bergman RN, PhD3, M ... | |
|
12. Acarbose Treatment and the Risk of Cardiovascular Disease and Hypertension in Patients with Impaired Glucose Tolerance: The STOP-NIDDM Trial |
| JAMAChiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M; STOP-NIDDM Trial Research Group.CONTEXT: The worldwide explosive increase in type 2 diabete ... | |
|
13. The Significance of Impaired Fasting Glucose Versus Impaired Glucose Tolerance: Importance of Insulin Secretion and Resistance |
| Diabetes Care Carnevale Schianca GP, Rossi A, Sainaghi PP, Maduli E, Bartoli E From the Dipartimento di Scienze Mediche (Internal Medicine), Università del Piemonte Orien ... | |
|
14. Identification of Persons at High Risk for Type 2 Diabetes Mellitus: Do We Need the Oral Glucose Tolerance Test? |
| Annals of Internal Medicine Stern MP, Williams K, Haffner SM BACKGROUND: The standard method of identifying persons at high risk for type 2 diabetes mellitus involves detection of i ... | |
|
15. Prevalence of Abnormal Glucose Tolerance in Three Ethnic Groups |
| Harris MI et al. Diabetes Care. 1998;21:518-524. This slide shows age-standardized prevalence of impaired fasting glucose (IFG) for people aged 20 years or older, and impaired glucose tolerance (IGT) for people aged 40 to 74 year ... | |
|
16. Insulin Secretory Responses to Rising and Falling Glucose Concentrations Are Delayed in Subjects With Impaired Glucose Tolerance. |
| Diabetologia Insulin Secretory Responses to Rising and Falling Glucose Concentrations Are Delayed in Subjects With Impaired Glucose Tolerance D. A. Ehrmann 1, E. Breda 2, M. K. Cavaghan1, S. Bajramovic1, J. Imperial1, G. Toffolo 2, C. Cobelli 2, K. S. Polonsky 3 1 Department of Medicine, Sectio ... | |
|
17. Deficiency of Total and Nonglycosylated Amylin in Plasma Characterizes Subjects With Impaired Glucose Tolerance and Type 2 Diabetes |
| Journal of Clinical Endocrinology & Metabolism Makimattila S, Fineman MS, Yki-Jravinen H.J Clin Endocrinol Metab. 2000;85:2822-2827. This study was undertaken to ... | |
|
18. Characterisation of b-Cell Dysfunction of Impaired Glucose Tolerance: Evidence for Impairment of Incretin-Induced Insulin Secretion |
| Diabetologia Characterisation of b-Cell Dysfunction of Impaired Glucose Tolerance: Evidence for Impairment of Incretin-Induced Insulin SecretionFritsche A, Stefan N, Hardt E, Häring H, Stumvoll M.Diabetologia. 2000;43:852-858. Aims/hypothesisOur studies were undertaken to characterise the defect ... | |
|
19. Response of Pancreatic B-Cells to Improved Insulin Sensitivity in Women at High Risk for Type 2 Diabetes |
| Diabetes Response of Pancreatic b-Cells to Improved Insulin Sensitivity in Women at High Risk for Type 2 DiabetesBuchanan TA, Xiang AH, Peters RK, et al.Diabetes. 2000;49:782-788. The purpose of this study was to examine the response of pancreatic b-cells to changes in insulin sensitivity in wome ... | |
|
20. Incidence of Diabetes Mellitus and Impaired Glucose Tolerance in Children and Adolescents Receiving Growth-Hormone Treatment |
| Lancet Cutfield WS, Wilton P, Bennmarker H, et al.Lancet. 2000;355:610-613. Summary BackgroundGrowth hormone (GH) contributes to insulin resistance, but whether children t ... | |
|
21. Impaired Glucose Tolerance Is a Risk Factor for Cardiovascular Disease, but Not Impaired Fasting Glucose |
| Diabetes Care The Funagata Diabetes StudyTominaga M, Eguchi H, Manaka H, Igarashi K, Kato T, Sekikawa A. Diabetes Care. 1999;22:920-924. ObjectiveTo determine whether the new category of impai ... |
| Site Match | 17 Records found: [< 1 > of 1 Pages] |
|
1. Microvascular and Macrovascular Reactivity Is Reduced in Subjects at Risk for Type 2 Diabetes Diabetes Microvascular and Macrovascular Reactivity Is Reduced in Subjects at Risk for Type 2 DiabetesCaballero AE, et al. The responses to SNP were similarly ... ... |
|
2. Relative Hyperproinsulinemia as a Sign of Islet Dysfunction in Women With Impaired Glucose Tolerance At fasting glucose, levels of insulin, proinsulin, or the proinsulin/insulin ratio (13.6 Ã?± 5.0% vs. 11.1 Ã?± 2.7%; P = NS) did not differ between NGT and IGT. Therefore, the IGT women had higher proinsulin/insulin ratios at 14 mmol/L (10.7 Ã?± 4.4% vs. 6.4 Ã?± 1.8%; P = 0.006) and more than 25 mmol/L glucose (11.4 Ã?± 5.2% vs. 6.7 Ã?± 2.1%; P = 0.007). The IGT group had increased APIRarg/AIRarg at fasting (2.2 Ã?± 1.4%... ... |
|
3. Insulin Secretory Responses to Rising and Falling Glucose Concentrations Are Delayed in Subjects With Impaired Glucose Tolerance. Diabetologia Insulin Secretory Responses to Rising and Falling Glucose Concentrations Are Delayed in Subjects With Impaired Glucose Tolerance D. A. Ehrmann >... ... |
|
4. Usefulness of preoperative oral glucose tolerance testing for perioperative risk stratification in patients scheduled for elective vascular surgery Usefulness of preoperative oral glucose tolerance testing for perioperative risk stratification in patients scheduled for elective vascular surgery Patients scheduled for major vascular surgery are screened for cardiac risk factors using standardized risk indexes, including diabetes mellitus (DM). However, an oral glucose tolerance test (OGTT) could significantly improve the detection of DM and impaired glucose tolerance (IGT... ... |
|
5. Type 2 Diabetes Prevention Studies Type 2 Diabetes Prevention Studies Both behavioral and pharmacologic ... ... |
|
6. Prevalence of Diabetes, IFG, and IGT in US Population 40-74 Years of Age Prevalence of Diabetes, IFG, and IGT in US Population 40-74 Years of Age This figure compares the prevalences of diabetes, impaired fasting glucose (IFG), and impaired glucose tolerance (IGT) in US adults between the ages of 40 and 74 as determined by the Second and by the Third National Health and Nutrition Examination Surveys. >A href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&... ... |
|
7. Impaired Glucose Tolerance, Type 2 Diabetes, and Carotid Wall Thickness Diabetes Care Impaired Glucose Tolerance, Type 2 Diabetes, and Carotid Wall Thickness Wagenknecht LE, D"Agostino RB, Haffner SM, Savage PJ, Rewers M Diabetes Care. >font face="Verdana, Helvetica, sans-serif" size... ... |
|
8. Risk of Type 2 Diabetes in People With Impaired Glucose Tolerance >A href="http://www.ncbi.nlm.nih.gov/htbin-post/Entrez/query? db=m&form=6&dopt=r&uid=12196473" target... ... |
|
9. Effects of ramipril and rosiglitazone on cardiovascular and renal outcomes in people with impaired glucose tolerance or impaired fasting glucose: result of the (DREAM) trial. Effects of ramipril and rosiglitazone on cardiovascular and renal outcomes in people with impaired glucose tolerance or impaired fasting glucose: results of the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) trial. gilles.dagenais@crhl.ulaval.ca OBJECTIVE: Impaired glucose tolerance (IGT) and/or impaired fasting glucose (IFG) are risk factors for diabetes, cardiovascular disease (... ... |
|
10. The 1997 American Diabetes Association and 1999 World Health Organization Criteria for Hyperglycemia in the Diagnosis and Prediction of Diabetes Diabetes Care The 1997 American Diabetes Association and 1999 World Health Organization Criteria for Hyperglycemia in the Diagnosis and Prediction of DiabetesGabir MM, Hanson RL, Dabelea D, et al. ResultsThe frequency of diabetes was 12.5% by... ... |
|
11. Rationale, design, and baseline characteristics for a large international trial of cardiovascular disease prevention in people with dysglycemia: the ORIGIN Trial (Outcome Reduction with an Initial Glargine Intervention). AIMS: Impaired fasting glucose (IFG), impaired glucose tolerance (IGT), and diabetes arise due to insufficient insulin secretion and are risk factors for cardiovascular (CV) events. RESULTS: A total of 12,612 (mean age 64, 35% women) people in 40 countries were randomized during a 2-year period ending December 2005. CONCLUSIONS: The ORIGIN trial will ... ... |
|
12. Microalbuminuria Is an Independent Component of the Insulin Resistance Syndrome Microalbuminuria Is an Independent Component of the Insulin Resistance Syndrome A study undertaken to determine whether microalbuminuria is associated with the insulin resistance syndrome independent of hypertension and type 2 diabetes involved 1,006 randomly selected persons older than age 40 years residing in a rural ... ... |
|
13. Impact of intensive lifestyle and metformin therapy on cardiovascular disease risk factors in the diabetes prevention program Impact of intensive lifestyle and metformin therapy on cardiovascular disease risk factors in the Diabetes Prevention ProgramRatner R, Goldberg R, Haffner S, Marcovina S, Orchard T, Fowler S, Temprosa M >SPAN style="FONT-SIZE: 10pt; FONT-FAMILY: Arial; mso-fareast-... ... |
|
14. Performance of Recommended Screening Tests for Undiagnosed Diabetes and Dysglycemia Diabetes Care Performance of Recommended Screening Tests for Undiagnosed Diabetes and Dysglycemia Deborah B. Rolka, MS, K. M. Venkat Narayan, MD, Theodore J. Thompson, MS, Dona Goldman, BSN, MPH, Joann Lindenmayer, DVM, MPH, Kate Alich, MS, RD,... ... |
|
15. Association of Hormone Replacement Therapy and Carotid Wall Thickness in Women With and Without Diabetes Diabetes Care Association of Hormone Replacement Therapy and Carotid Wall Thickness in Women With and Without Diabetes Dubuisson JT, Wagenknecht LE, D"Agostino RB, et al. Objective Atherosclerosis is ... ... |
|
16. The Natural Course of {beta}-Cell Function in Nondiabetic and Diabetic Individuals: The Insulin Resistance Atherosclerosis Study The Natural Course of {beta}-Cell Function in Nondiabetic and Diabetic Individuals: The Insulin Resistance Atherosclerosis StudyFesta A, Williams K, D'Agostino R, Jr., Wagenknecht LE, Haffner SM Data from the UKPDS (U.K. Prospective Diabetes ... ... |
|
17. The lipid triad in type 2 diabetes - prevalence and relevance of hypertriglyceridaemia/low high-density lipoprotein syndrome in type 2 diabetes Exp Clin Endocrinol Diabetes The Lipid Triad in ... ... |
|
